{"title":"Novel Biological Mechanisms in MDD Pathophysiology: Emerging Roles of Glymphatic Dysfunction, Ferroptosis, and Extracellular Vesicles (EVs).","authors":"Anjali Anand, Payal Mittal","doi":"10.2174/0118715249465563260901043608","DOIUrl":null,"url":null,"abstract":"<p><p>Major Depressive Disorder (MDD) is one of the world's most disabling conditions. The traditional model focuses on monoaminergic imbalance, neurotrophic deficits, and hypothalamic- pituitary-adrenal (HPA) axis dysfunction. However, this model does not fully account for the complex symptoms and treatment resistance observed in MDD. Recent research highlights new biological mechanisms: glymphatic dysfunction, ferroptosis, and Extracellular vesicles (EVs) signaling. These findings mark a significant shift in understanding MDD pathophysiology. This study systematically reviewed literature from PubMed, Scopus, and Web of Science (2018-2025). It identified 71 eligible studies with preclinical and clinical findings. Evidence shows that impaired glymphatic clearance disrupts the exchange between cerebrospinal fluid and the brain's interstitial fluid. A loss of aquaporin-4 (AQP4) polarization drives this disruption. The result is neuroinflammation, oxidative stress, and disturbed sleep. Ferroptosis is a type of iron-dependent cell death marked by lipid peroxidation and glutathione depletion. It reduces neuronal viability and plasticity in brain regions involved in mood regulation. This aggravates MDD. Meanwhile, changes in EV microRNA, proteins, and lipids affect neuroinflammatory signaling and synaptic integrity. These changes act both as mediators and biomarkers of disease progression. The interaction between these pathways increases oxidative stress, neuroinflammation, and synaptic dysfunction. Together, they constitute an interconnected pathophysiological framework of MDD biology. Therapeutic options include promoting glymphatic flow through sleep regulation, using ferroptosis inhibitors and antioxidants, and developing EV-based diagnostics and therapies. These mechanisms suggest MDD pathophysiology involves impaired glymphatic clearance, oxidative imbalance, and disrupted intercellular communication. They offer potential targets for mechanism-based, personalized treatment strategies.</p>","PeriodicalId":93930,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715249465563260901043608","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Major Depressive Disorder (MDD) is one of the world's most disabling conditions. The traditional model focuses on monoaminergic imbalance, neurotrophic deficits, and hypothalamic- pituitary-adrenal (HPA) axis dysfunction. However, this model does not fully account for the complex symptoms and treatment resistance observed in MDD. Recent research highlights new biological mechanisms: glymphatic dysfunction, ferroptosis, and Extracellular vesicles (EVs) signaling. These findings mark a significant shift in understanding MDD pathophysiology. This study systematically reviewed literature from PubMed, Scopus, and Web of Science (2018-2025). It identified 71 eligible studies with preclinical and clinical findings. Evidence shows that impaired glymphatic clearance disrupts the exchange between cerebrospinal fluid and the brain's interstitial fluid. A loss of aquaporin-4 (AQP4) polarization drives this disruption. The result is neuroinflammation, oxidative stress, and disturbed sleep. Ferroptosis is a type of iron-dependent cell death marked by lipid peroxidation and glutathione depletion. It reduces neuronal viability and plasticity in brain regions involved in mood regulation. This aggravates MDD. Meanwhile, changes in EV microRNA, proteins, and lipids affect neuroinflammatory signaling and synaptic integrity. These changes act both as mediators and biomarkers of disease progression. The interaction between these pathways increases oxidative stress, neuroinflammation, and synaptic dysfunction. Together, they constitute an interconnected pathophysiological framework of MDD biology. Therapeutic options include promoting glymphatic flow through sleep regulation, using ferroptosis inhibitors and antioxidants, and developing EV-based diagnostics and therapies. These mechanisms suggest MDD pathophysiology involves impaired glymphatic clearance, oxidative imbalance, and disrupted intercellular communication. They offer potential targets for mechanism-based, personalized treatment strategies.
重度抑郁症(MDD)是世界上最致残的疾病之一。传统模型关注单胺能失衡、神经营养缺陷和下丘脑-垂体-肾上腺(HPA)轴功能障碍。然而,这个模型并不能完全解释在重度抑郁症中观察到的复杂症状和治疗耐药性。最近的研究强调了新的生物学机制:淋巴功能障碍、铁下垂和细胞外囊泡(EVs)信号。这些发现标志着理解重度抑郁症病理生理学的重大转变。本研究系统地回顾了PubMed、Scopus和Web of Science(2018-2025)的文献。它确定了71项具有临床前和临床结果的合格研究。有证据表明,受损的淋巴清除破坏了脑脊液和脑间质液之间的交换。水通道蛋白-4 (AQP4)极化的缺失导致了这种破坏。其结果是神经炎症、氧化应激和睡眠紊乱。铁下垂是一种以脂质过氧化和谷胱甘肽耗竭为特征的铁依赖性细胞死亡。它降低了大脑中参与情绪调节区域的神经元活力和可塑性。这加重了重度抑郁症。同时,EV microRNA、蛋白和脂质的变化影响神经炎症信号传导和突触完整性。这些变化既是疾病进展的介质,也是疾病进展的生物标志物。这些通路之间的相互作用增加了氧化应激、神经炎症和突触功能障碍。它们共同构成了一个相互关联的MDD生物学病理生理框架。治疗选择包括通过睡眠调节促进淋巴流动,使用铁下垂抑制剂和抗氧化剂,以及开发基于ev的诊断和治疗方法。这些机制表明,MDD的病理生理包括淋巴清除受损、氧化失衡和细胞间通讯中断。它们为基于机制的个性化治疗策略提供了潜在的目标。